Second Tunisian case of Anti –Tja mediated recurrent abortions

##plugins.themes.academic_pro.article.main##

Hager Zarrouk
Hedi Belleli
Asma Mahfoudh
Nejia Chalfouh
Houda Kaabi
Hmida Slama

Abstract

The diagnosis and the treatment of rare phenotypes remain a problematic situation in many countries especially in Tunisia. Individuals with rare phenotype may develop clinically significant red cell antibodies directed against the high incidence Antigens they lack.
A 35 years old patient was referred to our laboratory to explain a high incidence (twelve) of recurrent miscarriage during the first and second terms of pregnancy. This patient was grouped as O Rhesus: 1, -2, -3, 4, 5 K:-1. In her plasma we identified a pan-reactive anti-PP1PK antibody (anti-Tja) recognized to be responsible of spontaneous recurrent abortions. The red cell phenotype was P1 and Tja negative.
More investigations concluded to the absence of auto and other allo-antibodies association. Therapeutic plasmapheresis from early stages was suggested for the future pregnancy to remove anti-public antibodies in order to maintain normal placenta functions.
The Anti-Tja antibody, naturally occurring in patients with rare p phenotype, has the ability to induce recurrent spontaneous miscarriages and to cause immediate hemolytic transfusion reactions. Despite the absence of compatible donors in her family, this patient is not in an impasse situation because two donors with the same phenotype were identified when investigating a first case in 2013.

Keywords:

anti- Tja, anti-public antibody, recurrent miscarriages, rare phenotype,

##plugins.themes.academic_pro.article.details##

References

  1. T Peyrard, B-N Pham, P-Y Le Pennec, P Rouger. Les phénotypes érythrocytaires rares : un enjeu de santé publique. Transfusion clinique et biologique 15. 2008;109-119
  2. S Nance, E.A Scharberg, N Thornton, V Yahalom, I Sareneva, B C Lomas-Francis. International rare donor panels: a review. Vox sanguinis 2016;110: 209-218.
  3. D. Wirthner, P. Hohlfeld, J.-D. Tissot. Maladie hémolytique périnatale J Gynecol Obstet Biol Reprod 1998; 27 : 135-143.
  4. Georgette R. Benidt, Elizabeth A. Jaben, Jeffrey L. Winters, James R. Stubbs Identification of anti-PP1Pk in a blood donor and her family: A case report following her pregnancy and review. Transfusion and Apheresis Science 43.2010; 369-374
  5. S Derouich, A Ayachi, A Bouzid, N Khelifa, MJegham, M Mourali. AntiTja (PP1Pk) : Rare cause of recurrent early abortion. La tunisie Medicale - 2016 ; Vol 94 (n°07) : 336
  6. K Haentjens-Verbeke, Ph Dufour, D Vinatier, N Tordjeman, JC Monnier, L Manessier. Anti-TJa Alloimmunization Two consecutive pregnancies of anti Tja carrying patient Fetal Diagan Ther 1996;11:120-125
  7. Hansson GC, Wazniowska K, Rock JA, Ness PM, Kickler TS, Shirey RS, et al. The glycosphingolipid composition of the placenta of a blood group P fetus delivered by a blood group Pk1 woman and analysis of the anti-globoside antibodies found in maternal serum. Arch Biochem Biophys 1988;260:168-76.
  8. MC Fernández-Jiménez, MT Jiménez-Marco, D Hernández, A González, F Omeñaca, C de la Cámara. Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti-PP1Pk or anti-K immunization: a report of two patients Vox Sanguinis.2001; 80 : 117-120